QNTM Latest Press Releases

-- November 5, 2026 --

Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Threshold Globe Newswire 5:00 PM

-- October 8, 2026 --

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares Globe Newswire 8:00 AM

-- October 6, 2026 --

Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis Globe Newswire 6:00 AM

-- September 30, 2026 --

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. Globe Newswire 8:00 AM

-- September 24, 2026 --

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO Globe Newswire 8:00 AM

-- September 17, 2026 --

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target Globe Newswire 8:00 AM

-- September 15, 2026 --

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto Globe Newswire 8:00 AM

-- September 14, 2026 --

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating 'Rare Moment' in MS Research Globe Newswire 8:30 AM

-- September 11, 2026 --

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials Globe Newswire 8:30 AM

-- September 10, 2026 --

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market Globe Newswire 8:30 AM

-- September 9, 2026 --

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment Globe Newswire 8:30 AM

-- September 8, 2026 --

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach Globe Newswire 8:30 AM

-- September 1, 2026 --

Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange Globe Newswire 7:00 PM

-- August 21, 2026 --

Quantum Biopharma Provides Corporate Update Globe Newswire 7:00 PM

-- August 14, 2026 --

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial Globe Newswire 7:00 AM

-- August 10, 2026 --

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis: Globe Newswire 7:00 AM

-- July 30, 2026 --

Quantum BioPharma Announces Closing of Debt Settlement Globe Newswire 12:18 AM

-- July 20, 2026 --

Quantum BioPharma Announces Intention to Settle Debt Globe Newswire 7:00 PM

-- July 7, 2026 --

Quantum BioPharma Provides Corporate Update Globe Newswire 7:00 PM

-- June 26, 2026 --

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis Globe Newswire 8:30 AM

-- June 25, 2026 --

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy Globe Newswire 8:30 AM

-- June 24, 2026 --

The Quest to Repair What Multiple Sclerosis Takes Away Globe Newswire 8:30 AM

-- June 23, 2026 --

Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach Globe Newswire 8:30 AM

-- June 22, 2026 --

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis Globe Newswire 8:30 AM

Market Data Delayed 15 Minutes